Why ACE Inhibitors Reduce the Renal Clearance of Lithium

How Lithium is Normally Handled by the Kidney

• ~75% is reabsorbed in the proximal tubule
• ~25% is reabsorbed in the distal tubule
• Only ~20% of the filtered load is ultimately excreted

The ACE Inhibitor Mechanism - Step by Step

• Stimulate proximal tubular Na⁺/H⁺ exchange (directly increasing proximal reabsorption)
• Stimulate aldosterone release from the adrenal cortex

Parallel Drug Classes That Cause the Same Effect

• Goodman & Gilman's The Pharmacological Basis of Therapeutics, Block 3
• Katzung's Basic and Clinical Pharmacology, 16th Edition, Block 13

Clinical Implications

• Lithium has a narrow therapeutic index (target: 0.6-1.25 mmol/L; toxic: >1.5 mmol/L). Even modest changes in clearance can push plasma levels into the toxic range.
• ACE inhibitors are generally avoided in lithium-treated patients. If used, lithium levels must be monitored closely and the dose reduced. - Comprehensive Clinical Nephrology, 7th Edition, p. 902
• The interaction can develop insidiously - patients can develop chronic lithium toxicity (tremor, ataxia, cognitive slowing, nephrogenic diabetes insipidus) even at "near-therapeutic" serum levels, because intracellular lithium accumulation precedes the rise in serum levels.
• The same mechanism explains why volume depletion from any cause (poor oral intake, diarrhea, fever) increases lithium toxicity risk.

ACE Inhibitors - Mechanism of Action and Uses

The RAAS: What ACE Does Normally

1. Low renal perfusion → juxtaglomerular cells release renin
2. Renin cleaves angiotensinogen → angiotensin I (inactive)
3. ACE (angiotensin-converting enzyme), located mainly in the pulmonary endothelium, cleaves angiotensin I → angiotensin II (highly active)
4. Angiotensin II causes:
   • Powerful vasoconstriction (via AT1 receptors on vascular smooth muscle)
   • Aldosterone release from the adrenal cortex → Na⁺/water retention
   • Direct stimulation of proximal tubular Na⁺ reabsorption
   • Sympathetic nervous system activation
   • Cardiac and vascular remodeling (fibrosis, hypertrophy)

Mechanism of Action of ACE Inhibitors

• Blood pressure falls via reduced afterload (peripheral resistance) and reduced preload (less aldosterone/fluid retention)
• Cardiac output and heart rate are not significantly changed - no reflex tachycardia (unlike direct vasodilators), because baroreceptors reset and vagal tone is enhanced
• In the kidney: reduced efferent arteriolar resistance lowers intraglomerular capillary pressure → reduces proteinuria
• Katzung's Basic and Clinical Pharmacology, 16th Edition, pp. 278-279

Individual Drug Notes

Clinical Uses

• First-line agents, especially effective in high-renin states and in combination with diuretics or calcium channel blockers
• Lower BP without reflex tachycardia - safe in ischemic heart disease

• Class I indication - overwhelming trial evidence shows reduction in mortality, hospitalization, and improvement in symptoms
• Reduce both preload (less aldosterone → less Na⁺ retention) and afterload (vasodilation)
• Attenuate and reverse adverse cardiac remodeling (LV hypertrophy, fibrosis)
• Key trials: CONSENSUS, SOLVD, SAVE - Braunwald's Heart Disease, 2-Vol Set

• Started within hours of MI in patients with LV dysfunction (EF <40%) or signs of HF
• Reduce mortality, prevent post-MI LV remodeling, and reduce progression to overt HF

• Reduce intraglomerular capillary pressure by dilating the efferent arteriole
• Decrease proteinuria and slow progression of CKD - recommended even without hypertension in diabetics with microalbuminuria
• Katzung's Basic and Clinical Pharmacology, 16th Edition, p. 278

• Reduce proteinuria and stabilize GFR by lowering glomerular capillary pressure
• Renoprotective independent of BP lowering

• The HOPE trial showed ramipril reduced MI, stroke, and cardiovascular death in high-risk patients without HF
• Evidence suggests ACE inhibitors also reduce the incidence of new-onset diabetes

• Cause regression of LVH - superior to some other antihypertensives in this regard

Adverse Effects

• Katzung's Basic and Clinical Pharmacology, 16th Edition, p. 279

Contraindications

• Pregnancy (2nd and 3rd trimester - absolute; 1st trimester - relative)
• Bilateral renal artery stenosis (or stenosis of solitary kidney)
• Prior ACE inhibitor-induced angioedema
• Hyperkalemia (K⁺ >5.5 mEq/L)
• Avoid combining with ARBs or aliskiren (dual RAAS blockade - increased toxicity without added benefit in clinical trials)

ACE Inhibitors vs. ARBs - Key Distinction

Type 2 Diabetes Mellitus - Drug Treatment Plan

Step-by-Step Explanation

STEP 1 - Lifestyle Modification (ALL patients, at diagnosis)

• Diet: Caloric restriction, low glycemic index foods, Mediterranean or low-carb diet
• Exercise: ≥150 min/week of moderate aerobic activity + resistance training
• Weight loss: Target 5-10% body weight reduction
• Diabetes education and self-monitoring of glucose
• Smoking cessation

DECISION POINT 1: Is HbA1c ≥1.5% above target OR is the patient symptomatic?

• YES → Start with dual therapy or insulin immediately (don't wait for monotherapy to fail)
• NO → Proceed to Step 2

STEP 2 - First-Line: METFORMIN

DECISION POINT 2: Compelling Comorbidity?

STEP 3 - Dual Therapy (if HbA1c not at target after 3 months)

STEP 4 - Triple Therapy (if HbA1c still not at target)

STEP 5 - Insulin Therapy

• HbA1c >10% at diagnosis
• Symptomatic hyperglycemia (polyuria, polydipsia, weight loss)
• Failure of 3+ oral agents
• Acute illness, surgery, pregnancy
• Catabolism, significant weight loss

Start: Basal insulin (glargine, detemir, degludec)
       → 10 units/night OR 0.1-0.2 units/kg at bedtime
       → Titrate by 2 units every 3 days until fasting glucose 80-130 mg/dL

If postprandial glucose still high:
       → Add bolus insulin (lispro, aspart, glulisine) before largest meal
       → Progress to full basal-bolus regimen (4 injections/day)

Monitoring Throughout All Steps

Key 2026 ADA Updates (vs. older guidelines)

• Early combination therapy is now actively encouraged rather than stepwise monotherapy escalation
• GLP-1 RAs and SGLT2i are preferred add-ons regardless of HbA1c when CV/renal comorbidities exist
• Tirzepatide (dual GIP/GLP-1) recognized as highly effective for both glycemia and weight
• Avoid combining ACE inhibitor + ARB; avoid dual RAAS blockade
• Metformin + SGLT2i is now often recommended as a starting combination in many high-risk patients